GPC Biotech has initiated a Phase I study evaluating the company's lead drug candidate, satraplatin, in combination with Xeloda (capecitabine) in patients with advanced solid tumors.
The open-label study is being conducted at Northwestern University Medical Center in Chicago. The trial is expected to enroll up to 24 patients.
